Table 2.

Clinical response to TIL therapy in PD-1-naïve patients vs PD-1 progressors

	No prior αPD-1	Prior αPD-1±αCTLA-4
	n=32	n=23
Response rate*	42%	32%
Median OS (months)	19.6	14
Median PFS (months)	3.9	2.8
DOR both CR and PR, median (months)	32.2	7.6
# CR	5	1
DOR median (months)	54.8	41‡
DOR min (months)	13.2	41‡
DOR max (months)	83.1	41‡
DOR range (months)	(13.2–83.1‡)	(41‡)
# PR	8	6
DOR median (months)	11.3	6.2
DOR min (months)	7.8	2.7
DOR max (months)	76.1‡	28.6
DOR range (months)	(7.8–76.1‡)	(2.7–28.6)
# Ongoing responses (CR/PR)	5 (3/2)	2 (1/1)

*One patient in each group was not evaluable for response.

†Duration of response.

‡Ongoing response.

CR, complete response; DOR, duration of response; OS, overall survival; PD-1, programmed cell death protein 1; PFS, progression-free survival; PR, partial response; TIL, tumor-infiltrating lymphocytes.